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Abstract Islets of Langerhans need to maintain their round
morphology and to be fast revascularized after transplan-
tation to preserve functional insulin secretion in response to
glucose stimulation. For this purpose, a non-cell-adhesive
environment is preferable for their embedding. Conversely,
nutrient and oxygen supply to islets is guaranteed by
capillary ingrowth within the construct and this can only be
achieved in a matrix that provides adhesion cues for cells. In
this study, two different approaches are explored, which are
both based on a layered architecture, in order to combine
these two opposite requirements. A non-adhesive islet
encapsulation layer is based on polyethyleneglycole dia-
crylate (PEGDA). This first layer is combined with a second
hydrogel based on thiolated-gelatin, thiolated-heparin and
thiolated-hyaluronic acid providing cues for endothelial cell
adhesion and acting as a growth factor releasing matrix. In
an alternative approach, a conformal PEGDA coating is
covalently applied on the surface of the islets. The coated
islets are subsequently embedded in the previously
mentioned hydrogel containing thiolated glycosaminogly-
cans. The suitability of this approach as a matrix for con-
trolled growth factor release has been demonstrated by
studying the controlled release of VEGF and bFGF for
14 days. Preliminary tube formation has been quantified on
the growth factor loaded hydrogels. This approach should
facilitate blood vessel ingrowth towards the embedded islets




1.1 Lorenzo Moroni—Reflections on career goals
I was recruited as a Ph.D. student by Isotis Orthobiologics,
among the first tissue engineering companies in the world,
in 2003 to develop scaffold technologies for osteochondral
regeneration. The 4 years spent at Isotis were thrilling. I was
embedded in a fermenting environment, where every Ph.D.
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student was incentivized to push own boundaries, looking
for creativity and innovation while combining fundamental
science with a critical view on valorization. After receiving
my Ph.D. degree in 2006 at Twente University, I went to
USA at Johns Hopkins University. As a post-doc in the
Elisseeff lab, I focused on hydrogels and stem cells. In
2008, I was appointed the Musculoskeletal Tissue Bank
R&D director of Rizzoli Orthopedic Institute, where I
investigated the use of stem cells from alternative sources
and the development of novel biomaterials for skeletal
regeneration. These were formative years, where I could
sharpen my scientific thinking, expand my hands-on skills,
and move the first steps towardsc acquisition for new pro-
jects funding. From 2009 till 2014, I joined again Twente
University, where I got tenured in the Tissue Regeneration
department. Since 2014, I work at Maastricht University
and in 2016 I became professor in biofabrication for
regenerative medicine at the MERLN Institute for
Technology-Inspired Regenerative Medicine.
In these years, I was infused with an interdisciplinary and
intercultural mentality, where building an international
network and expanding my horizons beyond the borders of
my own country were pivotal to my career development.
These values together with patience, perseverance, and
tenacity in pursuing our scientific goals are what I try my
best to transfer to my group today.
The major limitation encountered so far in tissue engi-
neered constructs is the ingrowth of a suitable vascular bed,
able to sustain in short time after transplantation the meta-
bolic needs of the newly implanted tissue. This restriction
becomes more stringent for clinically relevant implants
containing sufficient amount of cells for restoring a lost
function in the body, and when a highly metabolically
active organ is considered [1]. Islet of Langerhans are
organules in the body having one of the highest blood
supply. Although islets account only for 1–2% of the total
pancreatic mass, they receive up to 5–15% of the total
pancreatic blood flow [2]. In clinical islet transplantation
(CIT), islets are injected into the portal vein of the recipient,
where they settle and start producing insulin in response to
glucose stimulation [3–5]. Before injection, islets must be
isolated from the pancreatic matrix by an enzymatic
digestion that disrupts the extracellular matrix and the
associated dense network of capillaries [6]. The loss of the
islets’ vascular bed limits their ability to functionally
respond to glucose stimulation and to ultimately achieve a
successful transplantation [7, 8]. Due to islets loss of
functionality, long term outcome for islet transplantation in
the portal vein is suboptimal and less than 50% of the
patients still remain insulin independent 5 years after
treatment [9]. In addition to poor revascularization, other
factors like instant blood mediated inflammatory reaction
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and complement activation (IBMIR), recurrent auto-
immunity [10] and allo-immune response [11] account for
islets loss of functionality in the first phases after
transplantation.
Many strategies for the creation of vascular beds have
been developed by several authors in the past few years. In
many of these approaches, complex networks are created
using 3D printing or microfluidic devices [12]. The pre-
sented results are remarkable, but these approaches are
characterized by difficult applicability to clinical strategies.
Some other approaches used elegant but technically com-
plex microlithography techniques [13] which are only
applicable to small scale devices.
A simpler, but equally effective approach has been
attempted by stimulating blood vessel ingrowth using
growth factors embedded in hydrogels [14–18]. By tuning
their controlled release in time and their spatial distribution,
researchers aimed at recreating the initial phases of phy-
siological angiogenesis. It has been extensively proven that
this simple but effective technique is able to induce blood
vessels ingrowth in vivo [17, 18]. Such an approach has
been tried with different hydrogels [15, 19–22], but the
most effective ones have been demonstrated to be those
introducing in their structure heparin, hyaluronic acid or
binding sites for growth factor stabilization and controlled
release [17, 18].
Hydrogels have shown their potential not only for
growth factor delivery purposes, but have also been
extensively used for islet encapsulation. Alginate has his-
torically been the first choice for islet encapsulation, both in
micro capsules [23, 24] as well for macro chamber devices
for artificial pancreas [25]. The main purpose addressed by
these studies was to provide a delivery vehicle for islet
transplantation and containment, together with some degree
of immunoprotection. The leading hypothesis behind these
studies was that a properly tuned hydrogel mesh around the
islets could prevent antibodies and cytokines to interact with
the embedded tissue, and consequently, the recurrent attack
of the immune system to allogeneic transplanted islets [26].
Such an approach has the overall aim to dismiss conven-
tional immunosuppression regimen by substituting it with a
shielding capsule which could prevent antibodies and
cytokines to interact with the embedded tissue [24]. Finding
a balance between proper insulin and nutrient diffusion to
the islets and impeding antibodies and cytokines to
permeate through the protection capsule has proven to be a
very challenging task. PEGDA hydrogels have the advan-
tage of a very defined and tunable molecular weight and
chemical functionalization. Immunoprotection strategies
using PEGDA functionalization have been attempted by
creating a conformal coating of PEGDA on the islet surface
[27–29]. Reactive groups like N-hydroxy-succinimide
(NHS) or succinimidyl-valeric-acid (SVA) have the
potential to react with amino groups exposed on proteins on
islet’s surface and create a conformal, single molecule thick
coating, on the islet itself [30].
Literature has demonstrated the immunoprotective
properties of conformal islet coating by PEGylation, with-
out the need for embedding them in micrometer sized
hydrogel capsules [28]. This approach could minimize
limitations arising from nutrient diffusion impairments to
the islets while maintaining the immunoprotection concept.
This study presents a combination of all the aforemen-
tioned concepts, merged into a single multifunctional con-
struct. A combination of PEGDA hydrogels for islets
embedding acts as a vehicle for islets delivery and retention,
while a PEGDA based layer enriched with thiolated-gelatin
and extracellular matrix proteoglycans offers a cell adhesive
environment for enhanced attraction of blood vessels by the
controlled release of pro-angiogenic growth factors. In a
similar approach, the PEGDA layer for islet embedding is
reduced to a conformal coating of PEGDA covalently
bound to the islet surface proteins. This second approach
attempts to reduce nutrient diffusion limitations by using a
thinner PEGDA layer and could at the same time provide
immune-protective properties to the embedded tissue. These
coated islets are then embedded in the previously mentioned
hydrogel containing thiolated glycosaminoglycans for the
induction of vascularization.
A distinctive feature of such a construct is the fact that, in
both cases, the two layers are covalently bound to each
other by mean of free acryl groups on the surface of both
hydrogels (first approach, Fig. 1a) or islets surface (second
approach, Fig. 1b), creating in this way a unique, multi-
layered, and multifunctional construct for revascularization
of transplanted islets.
2 Materials and methods
2.1 Islet of langerhans and MIN6 cell culture and
pseudo-islets formation
Isolated human islets were kindly provided by the LUMC
Leiden (after informed donor consent and only if the
material could not be used for clinical transplantation).
Islets were cultured in CMRL medium (Cellgro) supple-
mented with 10% FBS and 1% Pen/Strep [31], 10 mM
Hepes (Gibco), 10 mM Glutamax (Gibco) and 10 mM
Nicotinamide (Sigma-Aldrich).
MIN6-B1 cells, derived from a mouse insulinoma, were
kindly provided by Dr. P. Halban, University Medical
Center, Geneva, Switzerland. Cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM,
Gibco) with 10% (v/v) FBS (Lonza), and antibiotics (100
U/mL penicillin, 100 mg/mL streptomycin, Gibco).
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Beta-mercaptoethanol (Gibco) was freshly added at every
medium change. Cells were cultured in standard culture
conditions at 37 degrees, 5% CO2 in humidified
atmosphere.
MIN6-B1 cells were used for the preparation of cell
aggregates as previously reported by our group [32].
Briefly, cells were cultured in sterile agarose microwells
(200 µm diameter) fabricated by pouring sterile agarose (3%
w/v UltraPureTM Gibco Invitrogen) on top of a pre-ster-
ilized, pre-fabricated polydimethylsiloxane (PDMS) mold
with micropillars of 200 µm in diameter. One million MIN6
cells were seeded on each agarose chip and cultured for two
days to allow for aggregate formation. So formed pseudo-
islet could be easily removed from the chip by flushing it
with some medium and used for further experiments.
2.2 Islet of Langerhans/MIN6 pseudo-islets embedding
in polyethylene glycol diacrylate gels
MIN6 pseudo-islets were resuspended in a sufficient
amount of 5% w/v poly(ethylene glycol diacrylate)
(PEGDA) with a molecular weight of 5000 (Laysan) in PBS
(Gibco). A 10% w/v solution of Irgacure 2959 (Basf) in
70% Ethanol was prepared and 10 µl added to 1 ml of
PEGDA solution prior to crosslink. Each sample was pre-
pared using 50 µl of the precursor PEGDA, additioned with
the photocrosslinker, and contained on average about 1400
MIN6 pseudo-islets.
For samples containing human collagen IV (Merck
Millipore) or human laminin (Sigma-aldrich), a 20 µg/ml
stock solution of protein was prepared in sterile PBS
(Gibco) and diluted to the working concentration of
10 µg/ml by using 10% w/v concentrated PEGDA solution
prior the addition of Irgacure (Basf). MIN6 pseudo-islets
were resuspended in the solution, 50 µl samples were
pipetted in a 96 well plate, and exposed to 356 nm UV light
for 10 min at 5 cm distance from the light source with an
intensity of 8.2 mW/cm2.
In case a bi-layered construct was prepared, the 50 µl
PEGDA sample containing aggregates was crosslinked on
top of a pre-gelled 50 µl vascularization gel.
2.3 Glucose induced insulin secretion test
Insulin secretion after glucose stimulation was tested on
either islets of Langerhans or MIN6 pseudo-islets by incu-
bating them in Krebs buffer (115 mM NaCl, 5 mM KCl, 24
mM NaHCO3 Sigma) supplemented with 2.2 mM CaCl2,
20 mM HEPES (Gibco), 2 mg/mL bovine serum albumin,
and 1 mMMgCl2 at pH 7.4 In case of testing MIN6 pseudo-
islets functionality, theophylline 10 mM (Sigma) was
added. This buffer was split into low (1.67 mM) and high
glucose (16.7 mM) buffer. Cells were washed and pre-
incubated for 90 min in low glucose buffer. Subsequently,
cells underwent a series of 45 min incubation in 250 µl of
either low glucose, high glucose, and finally again low
Fig. 1 Concept of the bilayered
constructs a Vascularization
hydrogel based on Michael type




acid. These ECM molecules are
able to provide an adhesion cues
for endothelial cells and act as a
controlled release compartment
for growth factor delivery. This
layer can be covalently
crosslinked with a PEGDA
based embedding layer for islet
of Langerhans encapsulation.
Collagen IV or laminin can be
mixed within the hydrogel mesh
to create a more favorable
environment for islet of
Langerhans. b Conformal
coating model where free amino
groups exposed on proteins on
the surface of islets are
covalently modified by PEG
chains. The free acrylate group
on the other extremity can react
with the thiol groups present in
the vascularization hydrogel via
Michael type reaction
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glucose buffer, alternated by washings. Two hundred and
thirty microlitres of glucose-induced insulin secretion test
samples were taken after each incubation and the amount of
insulin secreted by the cells upon glucose stimulation was
quantified by using either a human (for islet) or mouse
(MIN6 pseudo-islets) insulin ELISA kit (Mercodia).
2.4 Islet of Langerhans PEGylation and imaging of the
conformal PEGDA coating
Islets (1250 islet equivalent per sample) were washed 3
times in PBS and incubated for 1 h in a 12.5% w/v solution
of NHS-PEG-Biotin (Laysan) in PBS (Gibco) at pH 8,
additioned with 5 mM glucose. Islets were washed, fixed
with 10% w/v formalin solution for 3 min, and subsequently
incubated for an additional hour with a 20 µg/ml solution of
Streptavidin-FITC (Sigma-aldrich) protecting from light
[30]. PEGylated and control islets were imaged using an
EVOS digital microscope (EMS) equipped with an EVOS
light cube (EMS) for GFP imaging.
2.5 Islet of Langerhans PEGylation and embedding in
the vascularization hydrogel
Five hundred islet equivalent for each sample were washed
with PBS supplemented with 5 mM glucose and incubated
for 1 h in 350 µl of a 5% w/v solution of PEG-SVA-Acryl
(laysan) in PBS additioned with 5 mM glucose [30]. Sub-
sequently, islets were washed and sorted into 96 wells. Free
floating PEGylated islets were further cultured in CMRL
complete medium. PEGylated islets were also embedded
within the vascularization gel by resuspending them in the
gelin/heprasil/extralink mixture according to the specifica-
tion by the manufacturer and allow for spontaneous cross-
linking at room temperature prior to medium addition.
2.6 Vascularization hydrogel
A commercially available product, HyStem®-HP Hydrogel
Kit (ESI BIO), was used as a base for the vascularization
gel. The kit provides thiol-modified gelatin (Gelin), and a
combination of thiol-modified heparin and thiol-modified
hyaluronic acid (Heprasil) to be crosslinked upon addition
of polyethylene glycol diacrylate (Extralink). The hydrogel
can be used as a matrix for growth factors delivery and cell
attachment [17, 18].
Kit components were reconstituted according to the
manufacturer’s instruction. Only the Extralink vial was
reconstituted at a double concentration than the recom-
mended one. All components were mixed according to
Table 1. Typically, 400 µl of hydrogel precursor were pre-
pared for each condition and 75 µl samples were used in
each experiment. Basic fibroblast growth factor (bFGF) and
vascular endothelial growth factor (VEGF) (Peprotech)
were diluted in PBS (Gibco) with addition of 1% Bovine
Serum Albumin (BSA, Sigma) to a working solution of 10
µg/ml and used for further dilution upon hydrogel pre-
paration. Hydrogel gelation was induced by the Extralink
crosslinker, and gels were left for approximately 1 h to
allow for complete gelation.
2.7 Human umbilical vein endothelial cells culture
(HUVEC) and tube formation assay
HUVECs (Lonza) were used as a model for testing in vitro
activity and vascularization potential of growth factor loa-
ded hydrogels. HUVECs were cultured in EBM-2 basal
medium (Lonza) supplemented with the provided growth
factor bullet kit (EGM-2, Lonza). Cells from passage 2 to
passage 5 were used for tube formation assay. Cells were
stained with DiI (Invitrogen) according to the manu-
facturer’s specifications and incubated for 20 min at 37 °C.
After incubation, cells were washed with medium contain-
ing 2% serum. Cells were seeded on top of a preformed
hydrogel at a density of 15’000 cells/construct in a 96 well
plate [33]. Growth factor concentration in the hydrogel
were: 100 ng/ml basic fibroblast growth factor (bFGF,
Peprotech), 200 and 500 ng/ml vascular endothelial growth
factor (VEGF, Peprotech), combination of 100 ng/ml bFGF
with either 200 or 500 ng/ml VEGF. Control conditions
were 75 µl hydrogel without additional growth factors and
75 µl growth factor reduced Matrigel (BD). EGM-2 medium
used for tube formation assay was prepared without the
addition of VEGF or bFGF, so that the only source of
growth factor was the hydrogel only. Constructs were
imaged after 24 h using a BD pathway (BD) at 4×
Table 1 hydrogel preparation at
different growth factor
concentration according to the
manufacturer’s instructions.
bFGF and VEGF working













200 ng/ml VEGF 40 160 160 32 – 8
500 ng/ml VEGF 40 160 160 20 – 20
100 ng/mlbFGF 40 160 160 36 4 –
200 ng/ml VEGF+ 100 ng/ml bFGF 40 160 160 28 4 8
500 ng/ml VEGF+ 100 ng/ml bFGF 40 160 160 26 4 20
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magnification to measure the extent of the tube network
formed on the surface of the gel using ImageJ software
(NIH). The ImageJ software defines and quantifies para-
meters of the tubular network. Master segments are defined
as the elements of the network delimited by two junctions or
branching points in the network and calculates their length
in pixels. Nodes are defined as the branching points con-
necting two segments, of which one is not involved in the
formation of another junction (dead end). Junctions refer to
branching points connecting two or more master segments.
Moreover, two more elements that describe the formed
tubular structure are the mean mesh size (in pixels) of the
area delimited by master segments; and the number of
isolated segments, meaning the number of isolated seg-
ments on the picture, which are not incorporated within the
network.
2.8 Growth factor release study
Hydrogels with different growth factor concentrations
(Table 1) have been prepared as previously described. 500
µl of PBS (Gibco) with 0.1% Bovine Serum Albumin
(BSA, Sigma) were added to each sample and incubated at
37 C. Samples have been taken and the PBS/BSA 0.1%
refreshed upon sample withdrawal. Growth factor release
was measured by using a bFGF or VEGF ELISA kit (R&D)
according to the manufacturer’s protocol.
2.9 Statistical analysis
Statistical significance between groups was analyzed by
performing a One-way ANOVA followed by a Bonferroni
post-hoc test using IBM SPSS statistic 23 software. Data is
expressed as mean ± standard deviation and significant
differences are indicated with * (p ≤ 0.05).
3 Results
Bi-layered structures could be easily fabricated by cross-
linking PEGDA gels on top of a preformed vascularization
gel. The presence of free thiol groups on the surface of the
first hydrogel layer allowed for a covalent crosslinking of
the islet encapsulation layer on top of the vascularization
layer. Such bi-layered hydrogels were mechanically stable
and could be easily handled as a single construct. Similar
results were achieved in the second approach where islets
were modified with a conformal coating of bifunctional
PEG, where the SVA group reacted with free amino groups
exposed on the surface of the islets and the acryl group on
the other extremity of the PEG chain was available for the
reaction with acryl groups in the hydrogel matrix. Both
approaches, schematically represented in Fig. 1, combine
the favorable properties of non-adhesive and cell adhesive
layers, and can be independently tuned on the specific cell
type that will be embedded within the gel. In both cases it
was possible to combine the dual layer approach in a single
mechanically stable construct, in which the two layers were
able to crosslink with each other by establishing covalent
binding.
The vascularization layer allowed for embedding and
sustaining the release of growth factors for a period of
14 days (Fig. 2). No burst release was shown in the first day
of incubation both for bFGF and VEGF. The combined
release of two growth factors from the same hydrogel did
not show any difference in the release kinetic compared to
the same growth factor being released alone. In a period of
14 days, only about 1 ng was released from the 100 ng/ml
bFGF loaded hydrogels, accounting for about a seventh of
the total growth factor loading. In case of VEGF loaded
hydrogels, about 4 ng were released from the 200 ng/ml
VEGF or 200 ng/ml VEGF+ 100 ng/ml bFGF, accounting
for a fourth of the loaded amount. In case of the 500 ng/ml
VEGF and 500 ng/ml VEGF+ 100 ng/ml bFGF, a third
(~13 ng) of the originally loaded amount was cumulatively
released in a 14 days investigation time.
HUVEC seeded on the surface of the hydrogels adhered
to the material in about 4 h, showing a spread morphology
and cellular organization within 24 h. The degree of cell
organization with respect to preliminary tubular network
formation on the surface of the gels was dependent on the
growth factor dose embedded within the gel layer (Fig. 3).
Fig. 2 Release profile of VEGF and bFGF (different concentrations
and combinations) from the PEGDA/thiolated-Hyaluronic acid/gelatin/
heparin hydrogels for a release period of 14 days
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Fig. 3 Tube formation assay of HUVEC seeded on vascularization
hydrogels at different growth factors loads and combinations thereof.
Matrigel is used as positive control and quantification of master seg-
ments number, master segments length, nodes, mean mesh size,
isolated segments and junctions on tube formation assay of HUVEC
seeded on vascularization hydrogels. Significant differences between
groups are indicated with an (*) (p ≤ 0.05). Scale bar: 1 mm
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While in the control without growth factor cobblestone-
shaped cells were organized in clusters, when growth fac-
tors were present cells were more spread on the gel surface,
displayed a more elongated shape and connected to each
other with their cytoplasmatic extensions. In growth factor
loaded gels, polygonal areas delimited by cells were visible,
similar, although much less defined, than the ones formed
on Matrigel control gels. Although in none of the conditions
we were able to achieve the same degree of tube formation
obtained on Matrigel (positive control), it was possible to
quantify cellular organization in preliminary tubular struc-
ture (Fig. 3).
In all the conditions tested, Matrigel scored the highest in
master segments and master segments length, nodes, junc-
tions and mean mesh size, indicating the highest degree of
network organization. It also obtained the lowest score in
isolated segments, meaning that the great majority of the
cells were integrated in the network. Interestingly, hydro-
gels wthout growth factors were also analysed, but no
pattern on these images was detected, thus resulting in no
quantification. Overall, a comparable trend emerged from
the picture analysis in all the investigated parameters:
100 ng/ml bFGF alone and in combination with the
200 ng/ml VEGF being the conditions that showed an
increased tubular network formation in comparison to the
500 ng/ml VEGF alone and in combination with bFGF
100 ng/ml. Remarkably, gels with 100 ng/ml bFGF and 100
ng/ml bFGF+ 200 ng/ml VEGF scored no significant dif-
ference in comparison to Matrigel regarding nodes, mean
mesh size and junction formation. By comparing the com-
bination (bFGF+VEGF) vs. bFGF alone, it seemed that
bFGF was the mayor responsible for HUVEC organization
on the gel.
The functionality of MIN6 pseudo-islet embedded in the
bilayered constructs was tested and compared to control
free-floating aggregates. MIN6 aggregates functionality was
heavily reduced compared to the control when aggregates
were embedded in the single layer hydrogel (PEGDA only)
and completely absent when the embedding layer of
PEGDA was crosslinked on top of the vascularization layer.
Addition of extracellular matrix proteins as collagen or
laminin was not sufficient to rescue pseudo-islets function-
ality when embedded in the double layer construct (Fig. 4).
Successful surface modification with attachment of PEG
chains to the amino groups of proteins exposed on the islet
of Langerhans extracellular matrix was confirmed by a
fluorescent staining appearing on the surface of the islets
(Fig. 5).
Functionality of islets of Langerhans from two human
donors was analyzed at two time points and compared to the
functional response of free floating islets (untreated),
PEGylated free floating islets, islets embedded in PEGDA
hydrogels and PEGylated islet embedded in the gel. For all
donors and at both time points, functional insulin secretion
in response to high glucose stimulation was reduced com-
pared to the free floating control. Donor 2 performed overall
better with a higher stimulation index. At day 1, PEGylated
islets embedded in the gel showed still a functional
response. At day 7 all the conditions showed a borderline
functional behavior, but the embedding and PEGylation
procedure seemed to exert a detrimental effect on islet
functionality.
4 Discussion
PEGDA is a commonly used matrix for islet of Langerhans
encapsulation [34–38]. PEGDA has been widely used in
tissue engineering for cell encapsulation in cartilage regen-
eration [39–41], heart valves regeneration [42], islets [36] or
beta cells transplantation [34, 35, 38], and for controlled
delivery systems of pro-angiogenic growth factors [17, 18, 43]
with promising results. The main advantages of this syn-
thetic matrix are that it is highly defined, with tunable
molecular weight, hydrogel mesh size, mechanical proper-
ties, water content comparable to soft tissues in the body
[44], and ease of functionalization thanks to tunable free
binding groups within the matrix [44].
Although widely used, this very versatile system for
cell encapsulation also poses limitations. Being PEGDA
matrices inert and non-cell adhesive, considerable efforts
in functionalizing PEGDA hydrogels with peptides and
molecules of the extracellular matrix have been spent
in order to confer cell adhesion properties to the
Fig. 4 Stimulation index of free-floating MIN6 pseudo-islets, MIN6
aggregates embedded in the single layer PEGDA hydrogel and in a
double layered hydrogel without protein addition and in presence
of collagen 4 or laminin. Constructs have been incubated in low
(1.67 mM) and high (16.7 mM) glucose concentration. Stimulation
index is expressed as the ration between the amount of insulin secreted
in high glucose condition divided by the basal insulin secretion level
(in low glucose condition)
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material [45, 46]. Although chemical functionalization is
pretty straightforward, finding the right cocktail and con-
centrations of peptides for a specific cell type is not a trivial
subject. Weber and coworker [37] functionalized PEG gels
with collagen IV, laminin, a combination thereof, or pep-
tides derived from these proteins and found an increase in
insulin secretion. Many other adhesion peptides like RGD
sequences have been incorporated in PEG gels to improve
their adhesion properties [45, 46]. Also matrix metallopro-
tease sequences have been integrated in the mesh to allow
cells to rearrange the synthetic matrix [47]. Another way to
increase cell adhesion on PEGDA based hydrogels is to
include extracellular matrix molecules like heparin, hya-
luronic acid and collagen (or gelatin). Hyaluronic acid and
collagen molecules can enhance cell binding via specific
receptors like integrins [48] and CD44 [49]. Heparin is a
Fig. 5 Control (a,c) and pegilated (b,d) islet showing a NHS-PEG-
biotin layer covalently crosslinked on islet surface proteins and
visualized using a streptavidin-FITC conjugate. Scale bar: 1000 µm in
the upper row (a,b) and 400 µm lower row (c,d). The stimulation index
of islet of Langerhans from two donors in basal condition (1.67 mM
glucose) and high glucose stimulation (16.7 mM). Free floating islet
have been compared to pegilated free floating islet, islet embedded in
the construct and islets embedded in the gel after PEGylation. Both at
day 1 and day 7 functional response is reduced in all the experimental
groups
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common constituent of the extracellular matrix and is
widely used for binding and stabilizing growth factors.
In this study, a bi-layered scaffold concept offers the
advantage of combining all the aforementioned tunable
properties of PEGDA hydrogels in a unique, multi-
functional construct. Non-cell adhesive PEGDA layer
mixed with collagen and laminin can be used for islet of
Langerhans encapsulation, in the attempt of reducing cell
attachment and maintaining islets round morphology.
PEGDA layer with the addition of thiol-modified extra-
cellular matrix molecules like heparin, hyaluronic acid and
gelatin can serve to increase cell adhesion cues on the
hydrogel surface, act as a controlled release system for pro-
angiogenic growth factors and ultimately increase blood
vessels ingrowth in the construct.
In an alternative approach, the PEGDA layer has been
reduced to a conformal coating around the islet surface and
embedded into the vascularization layer. In both approa-
ches, both layers were covalently crosslinked to each other
in a single multilayered construct using free acryl groups
present either at the surface of both gels or on the surface of
the islets.
Thiol functionalized heparin, gelatin and hyaluronic acid
react spontaneously in mild, physiological conditions with
acryl groups on PEGDA forming a stable gel network via a
Michael-type addition reaction. This ECM enriched
PEGDA gel was able to sustain dual controlled release of
VEGF and bFGF for at least 14 days in vitro. The presence
of negatively charged glycosaminoglycans assured for slow
release of the growth factors from the gel and preservation
of their three dimensional structure and activity. The ability
of the released growth factor to induce primitive organiza-
tion of endothelial cells into elongated structures was still
lower than Matrigel, but the advantage of this semi-
synthetic system is that this is a fully characterized matrix,
in which known growth factor cocktails and proteins at
known concentration can be embedded.
Further work is required to find an optimal growth factor
combination but results reported in literature with similar
systems showed promising outcome [17, 18]. In these
papers, an increased vessel density with erythrocytes con-
fined in the capillary was found when growth factor loaded
hydrogels were implanted in a mouse ear. However, only
the induction of vascularization was tested, but no appli-
cation to an engineered tissue or organ was presented.
Furthermore, a more thorough characterization of the thio-
lated/PEGDA hydrogel mixtures should be considered,
including the quantification thiol/acrylates content or the
degree of substitution achieved on the different polymers.
Although we reduced as much as possible the air exposure
of the thiolated GAGs during their reaction with PEGDA,
we cannot exclude that disulfide bonds could be formed,
which are a notorious challenge to quantify in thiol-ene
hydrogel chemistry. Even when this was the case, hydrogels
could be formed. This could lead to think that the percen-
tage of such disulfide bonds could be neglected for the
purpose of the crosslinking reaction. Furthermore, being
these covalently bound hydrogel layers, we could exclude
phase separation phenomena that are more characteristic of
semi-interpenetrating networks. In vivo studies are neces-
sary to further study growth factor dose and release kinetic
on attraction of endothelial cells and revascularization of the
embedded islets. Moreover, in vivo degradation studies of
this semi-degradable matrix would provide more insights in
the release kinetic of the different growth factors and in the
timing of the revascularization process.
MIN6 pseudo-islets were used as a model for islets,
embedded in the PEGDA layer with or without the addition
of collagen IV or laminin. A reduced but still functional
response was detected in the single layer gels (thickness of
~1.5 mm), while functionality was lost when a double layer
was used, suggesting a limitation in nutrient diffusion
through the construct when its thickness is doubled (thick-
ness of ~3 mm) [50, 51]. A higher molecular weight
PEGDA could increase the mesh size of the hydrogel and
help diminishing nutrient diffusion limitations.
In an attempt to reduce nutrient diffusion limitations in a
bi-layered construct, a second strategy was developed and
consisted in the conformal coating of islets using a SVA-
functionalized PEGDA. SVA would react to free amino
groups exposed on proteins on the islet surface. The other
acryl functionalized end would react with thiol groups
exposed on the vascularization hydrogel. Such a conformal
coating on the surface of an islet would only account for a
few nanometers in thickness, which should not significantly
hamper nutrient diffusion. Moreover, nutrient and oxygen
diffusion should be facilitated also by the fact that islets are
directly embedded in the vascularization gel. We could
speculate that this gel presents higher mechanical proper-
ties, in the order of 100–350 kPa [52], compared to UV-
crosslinked PEGDA hydrogels (in the order of 50–60 kPa)
[53]. A lower concentration of PEGDA crosslinker and the
higher molecular weight of the ECM molecules crosslinked
within the mesh are expected to account for a larger pore
size in the gel mesh and weaker mechanical properties. All
these factors are known to result in a hydrogel mesh with
bigger distance between crosslinking points, and conse-
quently a larger mesh size, facilitating in this way nutrient
diffusion through the matrix, but contributing to weaker
mechanical properties. With regard to PEGDA conformal
coating, Lee and coworkers also claimed the possibility to
achieve immune-protective properties by using this kind of
strategy [27–29].
PEGDA binding to amino groups on islet was confirmed
by using a NHS-PEG-biotin. NHS-PEG-biotin was used in
this case instead of the SVA-PEGDA, because the available
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biotin functionalization would allow for streptavidin-FITC
detection of the successful functionalization. The reactivity
of NHS and SVA groups has been reported to be similar
[54]. Experimentally, effective PEGylation with SVA-
PEGDA was shown by the faster crosslinking speed and
increased stiffness of the vascularization gels where
PEGylated islets were embedded compared with gels where
non-PEGylated islets were embedded. This fact indirectly
confirms the effectiveness of SVA-PEGylation.
The functionality of embedded and PEGylated islets in
the vascularization layer remained borderline. The func-
tionality was reduced compared to the free floating control
condition; only highly functional islets (donor 2, stimulation
index > 4 at day1, >20 at day7) were able to still retain a
functional profile after PEGylation and embedding. This
fact is indicative for a quite harsh PEGylation reaction.
Nutrient diffusion limitation is believed to be the main
responsible for islet’s reduction in functionality in the bi-
layered constructs, but in case of PEGylated islets it might
not be the only reason for such reduction in functionality.
Although conformal coating creates a very thin layer, SVA-
PEGDA can still impair antibodies to interact with islets
surface antigens. It might be that a similar limitation occurs
for insulin diffusion from the islet. In this case, a con-
centration curve of different PEGDA/islet ratios during
PEGylation or lower SVA-PEGDA molecular weight might
help defining more friendly conditions for conformal coat-
ing of islets of Langerhans. Another possible explanation
might be that crucial proteins for glucose sensing, like
GLUT2 receptors might have undergone a conformational
change during PEGylation [55] or that the attachment of
PEG chains would impede glucose recognition by the
channel and its transport into the cytoplasm. Also in this
case, milder conditions for PEGDA-SVA conjugation to
islets should be investigated to reduce the possibility of
surface proteins inactivation. In summary, the concentration
of polyethylene glycol coupled on the surface, the reacting
groups, the length of the polymeric chain, quantity of islets
used in the coupling reaction and the donor variability in
islet functionality are all factors that need to be taken into
considerations in future studies.
After improving the functionality of the islets embedded
in the hydrogel, this system might offer a considerable
advantage in view of translation to the clinic, if compared to
conventional alginate or Matrigel embedding systems.
PEGDA based hydrogels are not degradable, covalently
crosslinked hydrogels, which offers a substantial advantage
for the reliability of this system in a long term after trans-
plantation, in particular if immunoprotection is desired.
Moreover, PEGDA offers the possibility of having com-
plete control on functionalization both of the islet embed-
ding layer as well as the vascularization layer. In contrast to
Matrigel, this synthetic tunable matrix can offer full control
on the growth factors type and concentration, eliminates the
problem of animal origin material and batch-to-batch var-
iation normally encountered when natural polymers are
used. The glicosaminoglycans used in the vascularization
layer (heparin and hyaluronic acid) are already approved for
human use in medical devices, while a point of attention
could be the use of gelatin. However, gelatin could be easily
substituted by adhesion peptides or human collagen
sequences. The stronger mechanical properties of these
hybrid hydrogels compared to PEGDA alone would not be
detrimental for clinical translation, as shown by the
mechanical stability of the constructs developed in this
study.
Envisioning a possible clinical translation, this system
offers several potential advantages in terms of safety, thanks
to the synthetic materials used, control over their produc-
tion, batch-to-batch variation, and control over their func-
tionalization with human derived proteins or
glycosaminoglycans. On the efficacy side, ameliorations in
the system are needed to better control islet functionality,
hydrogel mesh size, nutrient diffusion and PEGylation
conditions and should be implemented before pre-clinical
evaluation of the presented hydrogel construct.
5 Conclusions
PEGDA based hydrogels represent a versatile matrix for
cell embedding. The addition of extracellular matrix pro-
teins and thiol-modified glycosaminoglycans provided cell
adhesion properties and growth factor binding and release
capability to the otherwise inert PEGDA matrix. These
results show the potential of the vascularization layer to
attract and induce organization of an endothelial cell layer
in close proximity to islets of Langerhans.
More research is required in tuning mesh size properties
in the PEGDA layer for islets of Langerhans embedding,
since limited nutrient diffusion still seems to remain the
biggest limiting factor in islet functionality. The alternative
PEGylation approach reduces the thickness of the PEG
layer surrounding the islets. However, the PEGylation
procedure might irreversibly change the three dimensional
conformation of proteins exposed on the surface of the
islets.
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